A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- AstraZeneca AstraZeneca
AstraZeneca
Study Director - Peter Langmuir, Dir.Medic.Science
AstraZeneca
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Newecastle Upon Tyne, United Kingdom
- Research Site
Los Angeles, California, United States
- Research Site
Tampa, Florida, United States
- Research Site
Ann Arbor, Michigan, United States
- Research Site
New York, New York, United States
- Research Site
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Mar 2007
- Primary completion
- 27 Oct 2023
- Completion
- 27 Oct 2023
- Last update posted
- 22 Aug 2024
- Registered enrollment
- 37
- Registry id
- NCT00378482
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.